[Clinical analysis of chronic myeloid leukemia patients complicated with chronic kidney impairment during treatment with tyrosine kinase inhibitors].

Since the long-term safety profile of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) therapy has not been well characterized, we investigated renal impairment in 50 CML patients treated with TKI in our institute. During the median follow up period of 63 months, 29% of patients developed chronic kidney disease (CKD). Although the glomerular filtration rate (GFR) gradually declined, it dropped most markedly in the first 2 years after starting TKI. The CKD incidence was higher in patients older than 40 years or with decreased GFR, hypertension, or dyslipidemia at baseline. These findings highlight the necessity of careful monitoring of renal function in TKI-treated CML patients with these risk factors.